Will a blockbuster-level treatment emerge in the hepatitis C treatment market?

Followed by the hepatitis B treatment market, having excellent marketability even allowing a single-substance product to record KRW 150 billion prescriptions, the hepatitis C treatment market has also been accelerated as well.

BMS Korea announced the first domestic oral hepatitis C drug, Daklinza(daclatasvir) in combination with Sunvepra(asunaprevir) will be applied by the National Health Insu...